Clinical trials: Non-muscular Invasive Bladder Cancer
Urinary Bladder Neoplasms, BCG-Induced Cystitis
Early vs Delayed Intravesical Blad-Care During BCG Therapy
Intravesical Bacillus Calmette-Guérin (BCG) therapy is the standard adjuvant treatment for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC).
- Trial name
- PRO-GAG (NCT07495072)
- Testing
- Hyaluronic Acid and Chondroitin Sulfate (Blad-Care™)
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- BLAD-HYA Group
Non-muscle Invasive Bladder Cancer
En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer
Aim: To compare the surgical method of En Bloc resection to the conventional transurethral resection of non-muscle invasive bladder cancer (NMIBC) in terms of complete removal of tumour, specimen quality, and pathological…
- Trial name
- NCT05223491
- Testing
- En Bloc resection, Conventional TURB
- Where
- 11 sites in Denmark, Estonia and 3 more
- Volunteers
- 220 people
- Sponsor
- Jørgen Bjerggaard Jensen
Urinary Bladder Neoplasms, Urologic Neoplasms
SHTC - EUROPE-1 Synergo Hyperthermia-Chemotherapy by European Urologists' Research Operation Preserving Evolution Study I
A multi-institutional, prospective, randomised, open-label, superiority, comparative, active-controlled, phase 3 study. The study will compare Synergo RF-induced hyperthermia-chemotherapy (SHTC) plus mitomycin C (MMC) to standard…
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Urogenital Neoplasms, Neoplasms
- Trial name
- SHTC-EUROPE-1 (NCT02254915)
- Testing
- Synergo + MMC, Bacillus Calmette-Guérin
- Sponsor
- Medical Enterprises Europe B.V.
Bladder Cancer
Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression
This research study is studying the safety, tolerability, and tumor activity of the study drug known as rogaratinib as a possible treatment for bladder cancer.
- Trial name
- NCT04040725
- Testing
- Rogaratinib
- Sponsor
- Dana-Farber Cancer Institute
Bladder Cancer
Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer
Research Hypothesis Approximately 75% of patients with bladder cancer (BC) present with a disease confined to the mucosa (stage Ta, CIS) or submucosa (stage T1) (non-muscle invasive BC [NMIBC]). For high grade NMIBC, i.e.
- Trial name
- NCT03759496
- Testing
- Durvalumab
- Where
- Greece
- Volunteers
- 39 people
- Sponsor
- Hellenic GenitoUrinary Cancer Group
Bladder Cancer
Role of ERBT Plus Intravesical BCG in Intermediate-Risk or High-Risk NMBC
This is a prospective, multi-centre randomised trial comparing between cTURBT plus 1-year BCG therapy, and ERBT plus 1-year BCG therapy, in patients with intermediate-risk or high-risk NMIBC.
- Trial name
- NCT07724886
- Testing
- Conventional Transurethral Resection of Bladder Tumour, Transurethral En Bloc Resection of Bladder Tumour
- Where
- 2 sites in Hong Kong
- Volunteers
- 732 people
- Sponsor
- Chinese University of Hong Kong
Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
This phase II trial studies the effect of avelumab, gemcitabine and carboplatin before surgery compared with surgery alone in treating patients with muscle invasive bladder or upper urinary tract cancer who are not able to…
- Conditions
- Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8
- Trial name
- NCT04871529
- Testing
- Therapeutic Conventional Surgery, Avelumab, Gemcitabine Hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 6 people
- Sponsor
- SWOG Cancer Research Network
Bladder Cancer
Electromotive Mitomycin-C (EMDA-MMC) in Preventing Recurrences in High-risk Non-muscle-invasive Bladder Cancer
Disease recurrence and progression is a major issue in high risk non-muscle-invasive bladder cancer (NMIBC). The current study compares two adjuvant instillation therapies in the treatment of high risk NMIBC.
- Trial name
- FB10 (NCT03664869)
- Testing
- BCG instillation therapy, Sequential BCG and EMDA mitomycin C
- Where
- 7 sites in Finland
- Volunteers
- 300 people
- Sponsor
- Turku University Hospital
Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Neoplasms
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
A database has been created and will be used in which data will be collected in electronic format relating to adult patients who underwent one of the following endoscopic resection surgeries: TURBK, MAPPING, TURBK SECOND LOOK…
- Conditions
- Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Bladder Cancer
- Trial name
- NCT06167356
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- IRCCS San Raffaele
Bladder Cancer, Quality of Life
Impacts and Testing of the "Multi-domains Active-living Program" in Operable Non-Muscle Invasive Bladder Cancer Patients
Among bladder cancer, the majority of them (70%) are non-muscle-invasive bladder cancer (NMIBC). The survival time is even longer in NMIBC. Patients with NMIBC receive surgery or transurethral resection of bladder tumor (TURBT).
- Trial name
- NCT05739968
- Testing
- Usual care + oncology case manager (OCM) care, Multi-domains Active-living Program (MAP) with e-health enhanced intervention + usual care + oncology case manager (OCM) care
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- National Taiwan University Hospital
Non-Muscle-Invasive Bladder Cancer, Bladder Cancer
The Prognostic Impact of Tumor Location in Non-Muscle-Invasive Bladder Cancer Patients
Based on large sample size studies at home and abroad, the prognosis of patients with non-muscular invasive bladder cancer in different sites undergoing transurethral bladder tumor resection was determined, providing important…
- Trial name
- NCT06245759
- Testing
- This was a retrospective study and no patient intervention was performed
- Where
- China
- Volunteers
- 120,000 people
- Sponsor
- Huazhong University of Science and Technology
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
This Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- ENVISION (NCT05243550)
- Testing
- UGN-102
- Where
- 65 sites in United States, Austria and 8 more
- Volunteers
- 240 people
- Sponsor
- UroGen Pharma Ltd.
Urinary Bladder Diseases, Urinary Bladder Neoplasms
Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer
The study is designed to compare the efficacy and safety of 2 treatment types for the prevention of tumor recurrence of superficial bladder cancer: 1. A combination of bladder wall heating and local chemotherapy (Synergo) 2.
- Conditions
- Urinary Bladder Diseases, Urinary Bladder Neoplasms, Urinary Bladder Cancer, Malignant Tumor of Urinary Bladder
- Trial name
- NCT00384891
- Testing
- Synergo + MMC, Bacillus Calmette-Guérin
- Where
- 8 sites in Austria, Israel and 2 more
- Volunteers
- 190 people
- Sponsor
- Medical Enterprises Europe B.V.
Non Muscle Invasive Bladder Cancer
Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy
interventional study of intravesical chemotherapy and sistemic immunotherapy in NMIBC
- Trial name
- NCT06972615
- Testing
- intravesical Chemotherapy docetaxel/gemcitabine
- Where
- Argentina
- Volunteers
- 37 people
- Sponsor
- BLATAM
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study
This is a phase II study to determine the safety and efficacy of tislelizumab when given in combination with nab-paclitaxel as treatment for patients with high-risk non-muscle-invasive bladder cancer (HR NMIBC) which is not…
- Trial name
- NCT05418309
- Testing
- Tislelizumab Nab paclitaxel
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Tianjin Medical University Second Hospital
Non-muscle-invasive Bladder Cancer
Gemcitabine and Docetaxel Therapy in High-risk BCG-naive Patients With Non-muscle Invasive Bladder Cancer
Bacillus Calmette-Guerin (BCG) is the standard of care for high-risk patients with non-muscle invasive bladder cancer (NMIBC) after transurethral tumor resection.
- Trial name
- NCT05671900
- Testing
- Gemcitabine 1000 mg, Docetaxel 37.5g
- Where
- Croatia
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Centre Zagreb
Bladder Cancer
Safety and Pharmacokinetic Study of EO9(Intravesical Instillation)
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of intravesical instillation of EO9 in patients with non-muscle invasive bladder cancer (NMIBC).
- Trial name
- NCT01373398
- Testing
- EO9(Apaziquone)
- Where
- 2 sites in South Korea
- Volunteers
- 11 people
- Sponsor
- Handok Inc.
Carcinoma, Transitional Cell, Bladder Neoplasms
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
The main purpose of this research study is to evaluate the safety and dosing of CG0070.
- Trial name
- NCT00109655
- Testing
- Oncolytic adenovirus (serotype 5) - CG0070
- Where
- 10 sites in United States, Canada
- Volunteers
- 75 people
- Sponsor
- Cell Genesys
Superficial Bladder Cancer
Study of Immediate Post-Operative Intravesical Instillation of Chemophase® in Patients With Superficial Bladder Cancer
The purpose of this research study is to test the safety and tolerability of an experimental drug, Chemophase, a combination of recombinant human hyaluronidase, (an investigational synthetic enzyme also known as rHuPH20), and…
- Trial name
- IPOP (NCT00782587)
- Testing
- Chemophase
- Where
- 5 sites in United States
- Volunteers
- 14 people
- Sponsor
- Halozyme Therapeutics